The Claim
In HIV-infected adults on suppressive antiretroviral therapy, daily administration of rosuvastatin (10 mg) for 48 weeks reduces the proportion of activated CD4+ and CD8+ T cells (CD38+HLA-DR+) by 38.1% and 44.8%, respectively, compared to placebo, indicating a direct causal effect on adaptive immune activation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with HIV who are on antiretroviral therapy, taking 10 mg of rosuvastatin daily for 48 weeks reduces the percentage of activated CD4+ and CD8+ T cells by 38.1% and 44.8%, respectively, compared to a placebo.
See the scientific wording
In HIV-infected adults on suppressive antiretroviral therapy, daily rosuvastatin (10 mg) for 48 weeks reduces the proportion of activated CD4+ and CD8+ T cells (CD38+HLA-DR+) by 38.1% and 44.8%, respectively, compared to placebo, indicating a direct causal effect on adaptive immune activation.
Rosuvastatin blocks a key enzyme in cholesterol production, which reduces molecules needed to activate certain signaling proteins in immune and blood vessel cells. This turns down the production of inflammatory signals that tell T cells to become overactive. As a result, T cells stop displaying markers of activation and return to a quieter state.
What the research says
1 studyIn people with HIV who are on treatment, taking rosuvastatin for 48 weeks lowered the activity level of key immune cells by about 40%, meaning their immune systems were less overactive. This suggests the drug helps calm down the immune system.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.